Cosmo and takeda renew strategic manufacturing agreement for global supply of oral treatment for ulcerative colitis

Dublin, ireland--(newsfile corp. - august 8, 2025) - cosmo pharmaceuticals n.v. (six: copn), a global leader in ai-driven healthcare and specialty pharmaceuticals, today announced the renewal of its multi-year manufacturing and supply agreement with takeda (tse: 4502) (nyse: tak), to produce mesalazine mmx 1200 mg (marketed as lialda® in the usa and as mezavant in europe) oral, once-daily treatment for ulcerative colitis, reinforcing its position as a trusted partner for global production of key medicines.
TAK Ratings Summary
TAK Quant Ranking